文献速递乳腺癌放疗胸部肿瘤放疗

心脏放射剂量对接受辅助曲妥珠单抗和放疗的乳腺癌患者心脏毒性风险的显著影响

Significant Influence of Cardiac Radiation Dose on the Risk of Cardiotoxicity in Patients Receiving Adjuvant Trastuzumab and Radiation Therapy for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-11-15

该回顾性分析纳入1378例接受根治性手术和辅助曲妥珠单抗治疗的HER2阳性乳腺癌患者,其中959例接受术后放疗,419例未接受放疗。中位随访95.8个月后,69例(5.0%)发生癌症治疗相关心血管毒性(CTRCVT)。心脏放射剂量与曲妥珠单抗治疗期间及治疗后CTRCVT风险均显著相关。

要点

  • 心脏放射剂量与曲妥珠单抗治疗期间CTRCVT风险相关(OR 1.087,P=0.001)。
  • 心脏放射剂量与曲妥珠单抗治疗后CTRCVT风险相关(HR 1.177,P<0.001)。
  • 心脏V25Gy≥3%者8年CTRCVT-after T发生率显著高于<3%者(5.7% vs 1.5%,P=0.019)。

核心结论

  • 曲妥珠单抗治疗期间和治疗后发生的癌症治疗相关心血管毒性均与心脏放射剂量相关。
  • 评估心脏放射剂量对于预防曲妥珠单抗早期终止是必要的,早期终止可能导致更差结局。

研究设计与样本

  • 回顾性分析1378例接受根治性手术和辅助曲妥珠单抗治疗的乳腺癌患者,其中959例接受术后放疗,419例未接受放疗。
  • 从每例患者的放疗计划中提取心脏放射剂量,评估曲妥珠单抗治疗期间和治疗后CTRCVT的发生率及影响因素。

主要发现

  • 中位随访95.8个月(范围4.3-181.1个月),69例(5.0%)发生CTRCVT。
  • 曲妥珠单抗治疗期间CTRCVT检出41例(3.0%),其中27例(2.0%)因此停用曲妥珠单抗。
  • 曲妥珠单抗治疗后CTRCVT的8年发生率为2.2%。
  • 心脏放射剂量与曲妥珠单抗治疗期间CTRCVT风险相关(OR 1.087,P=0.001)及治疗后CTRCVT风险相关(HR 1.177,P<0.001)。
  • 未放疗组与放疗组曲妥珠单抗治疗后CTRCVT的8年发生率无显著差异(2.0% vs 2.4%,P=0.956)。

关键数值与推荐

  • 心脏V25Gy≥3%组与<3%组曲妥珠单抗治疗后CTRCVT的8年发生率分别为5.7%和1.5%(P=0.019)。
  • 未放疗组与放疗组曲妥珠单抗治疗后CTRCVT的8年发生率分别为2.0%和2.4%(P=0.956)。

临床怎么用

  • 原文结论指出,评估心脏放射剂量对于预防曲妥珠单抗早期终止是必要的,早期终止可能导致更差结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to analyze the incidence of cancer therapy-related cardiovascular toxicity (CTRCVT) and identify the radiation dosimetric and clinical risk factors for these events in patients with human epidermal growth factor receptor 2-positive breast cancer. METHODS AND MATERIALS: Data from 1378 patients who were treated with curative surgery and adjuvant trastuzumab for breast cancer were retrospectively analyzed. A total of 959 patients underwent postoperative radiation therapy (RT), whereas 419 patients were managed without RT (no-RT). CTRCVT were categorized according to the time of occurrence in relation to trastuzumab as follows: during trastuzumab cycles (CTRCVT-during T) or after completing trastuzumab (CTRCVT-after T). The cardiac radiation dose was extracted from the RT plan of each individual patient. The incidence of and contributing factors for CTRCVT-during T and -after T were evaluated. RESULTS: After a median follow-up of 95.8 months (range, 4.3-181.1 months), 69 patients (5.0%) had experienced CTRCVT. CTRCVT-during T was detected in 41 patients (3.0%), and the 8-year rate of CTRCVT-after T was 2.2%. Of the patients developing CTRCVT-during T, 27 (2.0%) discontinued trastuzumab. The cardiac radiation doses were significantly associated with the risk of both CTRCVT-during T (odds ratio, 1.087; P = .001) and -after T (hazard ratio, 1.177; P < .001). The 8-year rates of CTRCVT-after T were not significantly different between the no-RT and RT groups (2.0% vs 2.4%, P = .956). However, the rate was significantly higher in patients with heart V25Gy ≥3% compared with those with heart V25Gy <3% (5.7% vs 1.5%, P = .019). Patients who received <17 cycles of trastuzumab had worse oncological outcomes than those who received ≥17 cycles. CONCLUSIONS: Both CTRCVT-during T and -after T were associated with the cardiac radiation dose. Therefore, evaluation of the cardiac radiation dose is necessary to prevent early termination of trastuzumab treatment, which could lead to worse outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lee TH, Kim N, Kim EK, et al. Significant Influence of Cardiac Radiation Dose on the Risk of Cardiotoxicity in Patients Receiving Adjuvant Trastuzumab and Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39549762. doi:10.1016/j.ijrobp.2024.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。